SAN DIEGO, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired PubMatic, Inc. (NASDAQ: PUBM) securities between February 27, 2025 and August 11, 2025. PubMatic is a technology company that enables real time programmatic advertising transactions for advertisers, agencies, and demand side platforms (“DSPs”). For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call ...

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly misleading investors about its business prospects and competitive position during a specified period in 2025 [1][2]. Allegations - The complaint alleges that LifeMD's management materially overstated the company's competitive position and recklessly raised its 2025 guidance without properly accounting for rising customer acquisition costs in its RexMD segment and related to obesity treatment drugs [2]. - The statements made by the defendants regarding LifeMD's business operations and prospects were claimed to be materially false and misleading [2]. Financial Impact - Following the announcement of its second quarter 2025 results, which included a revision of full-year guidance due to "temporary challenges" in the RexMD business, LifeMD's stock price dropped by $5.31, or 44.8%, closing at $6.53 on August 6, 2025 [3]. Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must file their papers by October 27, 2025, although they can remain absent class members without taking action [4].

Core Viewpoint - A class action lawsuit has been filed against Snap Inc. for allegedly misleading investors about its business prospects, particularly regarding advertising revenue and growth expectations during the specified period [1][2]. Allegations - The complaint asserts that Snap's management created a false impression of having reliable information about expected advertising revenue while downplaying macroeconomic instability [2]. - Snap's optimistic reports on advertising growth were misleading, as they were overly reliant on the company's execution capabilities, which were already faltering [2]. Financial Results and Impact - On August 5, 2025, Snap reported a slowdown in advertising revenue growth, attributing it to issues with its ad platform, the timing of Ramadan, and minor changes [3]. - Following this announcement, Snap's stock price dropped from $9.39 per share to $7.78 per share, marking a decline of over 17% [3]. Class Action Participation - Shareholders may be eligible to participate in the class action against Snap Inc. and can contact Robbins LLP for more information [3]. - Individuals interested in serving as lead plaintiffs are encouraged to reach out, although participation in the case is not required for recovery eligibility [3]. About Robbins LLP - Robbins LLP is recognized for its work in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [4].

Group 1 - The core issue involves a class action lawsuit against Spectrum Pharmaceuticals, alleging false or misleading statements regarding its Pinnacle Study related to the drug poziotinib for lung cancer treatment [2] - The Lead Plaintiff appointment process for the class action has reopened, allowing shareholders who purchased shares between March 17, 2022, and September 22, 2022, to file their papers by September 24, 2025 [1][3] - Spectrum Pharmaceuticals focuses on acquiring, developing, and commercializing novel and targeted oncology therapies [1] Group 2 - The lawsuit claims that the company misrepresented information that could affect investor decisions, particularly concerning the clinical trial results of poziotinib [2] - Robbins LLP, the law firm involved, emphasizes that shareholders do not need to participate in the case to be eligible for recovery [3] - The firm operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless there is a recovery [4]

Core Viewpoint - A class action lawsuit has been filed against Nutex Health Inc. for failing to disclose fraudulent activities by its third-party arbitration vendor, HaloMD, which has raised concerns about the legitimacy of the company's reported revenues and financial health [1][2][3]. Group 1: Allegations and Concerns - The lawsuit alleges that Nutex Health Inc. did not disclose that HaloMD was involved in a scheme to defraud insurance companies, leading to unsustainable revenue from arbitration results [2]. - It is claimed that Nutex overstated its ability to remediate internal control weaknesses over financial reporting, affecting the accounting of stock-based compensation obligations [2]. - Blue Orca Capital's short report raised alarms about Nutex's 20-fold share price increase, attributing it to inflated billing practices by HaloMD, which could lead to a collapse in financial performance if these practices cease [3]. Group 2: Financial Impact - Following the announcement of a delay in filing quarterly financial statements due to incomplete accounting adjustments, Nutex's stock price dropped over 16% [4]. - The allegations suggest that if the fraudulent revenue streams are cut off, Nutex's stock could revert to penny-stock levels, indicating a significant risk to investors [3]. Group 3: Legal Proceedings - Shareholders are encouraged to participate in the class action lawsuit, with options to serve as lead plaintiff or remain as absent class members [5]. - Robbins LLP, the law firm handling the case, operates on a contingency fee basis, meaning shareholders incur no fees unless a recovery is achieved [6].

Core Viewpoint - A class action lawsuit has been filed against Snap Inc. for allegedly misleading investors about its business prospects, particularly regarding advertising revenue and growth expectations during the specified period [1][2]. Allegations - The complaint claims that Snap's management created a false impression of having reliable information about expected advertising revenue while downplaying macroeconomic instability [2]. - Snap's optimistic reports on advertising growth were found to be misleading, as they were overly reliant on the company's execution capabilities, which were already faltering [2]. Financial Results and Stock Impact - On August 5, 2025, Snap reported a slowdown in advertising revenue growth, attributing it to issues with its ad platform and external factors like the timing of Ramadan [3]. - Following this announcement, Snap's stock price dropped from $9.39 per share to $7.78 per share, marking a decline of over 17% [3]. Class Action Participation - Shareholders may be eligible to participate in the class action against Snap Inc. and can contact Robbins LLP for more information [3]. - Individuals interested in serving as lead plaintiffs are encouraged to reach out, although participation is not required for recovery eligibility [3]. About Robbins LLP - Robbins LLP is a recognized leader in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [4].

Core Viewpoint - A class action lawsuit has been filed against SelectQuote, Inc. for allegedly violating the False Claims Act by directing Medicare beneficiaries to insurers that compensated the company the most, rather than providing unbiased comparisons of insurance plans [1][2][3]. Group 1: Allegations and Legal Issues - The complaint alleges that SelectQuote failed to disclose that it directed Medicare beneficiaries to plans based on compensation rather than quality [2]. - SelectQuote is accused of not providing unbiased comparisons for Medicare Advantage plans and receiving illegal kickbacks from insurers [2]. - The U.S. Department of Justice filed a complaint stating that SelectQuote received "tens of millions of dollars" in illegal kickbacks from 2016 to 2021, leading to a significant drop in its stock price by 19.2% on May 1, 2025 [3]. Group 2: Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must file their papers by October 10, 2025 [4]. - Shareholders can remain absent class members and still be eligible for recovery without participating in the case [4]. Group 3: Company Background - Robbins LLP is a law firm specializing in shareholder rights litigation, dedicated to helping shareholders recover losses and improve corporate governance since 2002 [5].

Group 1 - A class action has been filed against Snap Inc. on behalf of investors who acquired its securities between April 29, 2025, and August 5, 2025 [1] - The allegations state that Snap misled investors about its advertising revenue and growth prospects, creating a false impression of reliable information while downplaying macroeconomic instability [2] - On August 5, 2025, Snap reported a slowdown in advertising revenue growth, attributing it to issues with its ad platform and other factors, leading to a stock price decline of over 17% from $9.39 to $7.78 per share [3] Group 2 - Robbins LLP is investigating the claims and encourages shareholders to participate in the class action, with options to serve as lead plaintiff or remain an absent class member [3] - The representation in the class action is on a contingency fee basis, meaning shareholders will not incur fees or expenses [4]

Core Viewpoint - A class action has been filed against Biohaven Ltd. for allegedly misleading investors regarding the viability of its drug candidates, particularly troriluzole and BHV-7000, during the period from March 24, 2023, to May 14, 2025 [1][2]. Group 1: Company Overview - Biohaven Ltd. is a biopharmaceutical company focused on developing therapies in immunology, neuroscience, and oncology [1]. - The company is working on several product candidates, including troriluzole for spinocerebellar ataxia (SCA) and BHV-7000 for bipolar disorder [1]. Group 2: Allegations and Legal Action - The class action alleges that Biohaven overstated the regulatory prospects and data sufficiency for troriluzole's approval for SCA [2]. - It is also claimed that the efficacy and clinical prospects of BHV-7000 for bipolar disorder were similarly overstated [2]. - The complaint suggests that the eventual revelation of these issues could significantly negatively impact Biohaven's business and financial condition [2]. Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs must file their papers by September 12, 2025 [3]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [3].

Core Viewpoint - A class action has been filed against CTO Realty Growth, Inc. for allegedly misleading investors about its financial health and sustainability of dividends during the specified period [1][2]. Allegations - The complaint states that CTO Realty Growth, Inc. did not disclose that its dividends were less sustainable than claimed, used deceptive practices to inflate its Adjusted Funds from Operations (AFFO), and overstated its business and financial prospects [2]. - Wolfpack Research's report accused CTO of not generating sufficient cash to cover its recurring capital expenditures and dividends since its conversion to a REIT in 2021, relying on a 70% increase in shares outstanding to cover a $38 million dividend shortfall from 2021 to 2024, and employing a manipulative definition of AFFO [3]. Financial Situation - The report highlighted that CTO had only $8.4 million in cash while facing quarterly dividends of $14 million and average recurring capital expenditures of $5.7 million, along with an additional $12 million in planned capital expenditures [3]. - Following the publication of the report, CTO's stock price fell over 5% [3]. Class Action Participation - Shareholders interested in participating in the class action must submit their papers by October 7, 2025, to serve as lead plaintiff [4]. - Shareholders can remain absent class members if they choose not to participate [4]. Company Background - Robbins LLP is noted for its focus on shareholder rights litigation, helping shareholders recover losses and improve corporate governance since 2002 [5].